Today: 9 June 2026
Upwork stock wobbles in premarket after 19% slide as Q1 outlook stuns traders
11 February 2026
2 mins read

Upwork stock wobbles in premarket after 19% slide as Q1 outlook stuns traders

New York, Feb 11, 2026, 06:22 EST — Premarket

  • Upwork shares held steady in premarket trading, following a sharp slide in the previous session.
  • The company’s bleak forecast for first-quarter revenue and profit triggered the selloff that followed the results.
  • Analysts are lowering their targets, citing worries about the company’s ability to pull off its enterprise strategy.

Upwork Inc shares slipped 0.1% to $15.20 premarket Wednesday, following a sharp 19% drop at the close in the previous session.

This is significant: the company wants investors to buy into its message that 2026 is shaping up as a rebound year—even though the immediate forecast calls for a weaker March quarter.

It’s a tricky time for online work platforms. Clients are tightening budgets, while automation is starting to chip away at some bread-and-butter freelance categories.

Upwork posted fourth-quarter revenue of $198.4 million late Monday, with GAAP net income coming in at $15.6 million. Looking ahead, the company is guiding for first-quarter revenue between $192 million and $197 million, and expects non-GAAP diluted EPS in the $0.26 to $0.28 range.

Upwork shares tumbled over 20% in after-hours trading after the company issued a first-quarter forecast that fell short of Wall Street’s expectations, overshadowing its results. The company projected full-year revenue between $835 million and $850 million, which was roughly in line with what analysts had been looking for.

Upwork is pitching this year as a pivot to AI-driven projects and deeper enterprise focus. CEO Hayden Brown described the company’s overhaul as setting it up for “human-plus-AI collaboration.” CFO Erica Gessert, addressing investors, pointed to 2026 as the target for “a year of accelerating growth.” Nasdaq

During the earnings call, executives said the first quarter will see higher expenses, with integration efforts and investments in Lifted—its enterprise arm—driving much of that. They also pointed to persistent headwinds in areas like writing and translation, where AI adoption continues to bite.

RBC Capital has lowered its price target on the stock to $20, down from $24, while maintaining a sector perform rating. The firm pointed to increased risks around execution and noted the company’s greater dependence on a second-half rebound following the enterprise transition.

Citizens cut its price target on Upwork to $22, down from $27, citing uncertainty around when enterprise revenue will kick in as the company adjusts its strategy.

UBS lowered its price target to $23, down from $26, though the firm maintained its buy rating. Analysts highlighted improving gross services value and a more favorable outlook for the second half, but noted it may be a while before confidence returns.

Bulls face a clear risk here. Should enterprise conversion stall beyond projections, what looks like a first-quarter trough could quickly resemble falling demand. If that happens, Upwork’s bet on a second-half rebound might not do much to keep sellers from pressing their case.

Investors want to see signs that client trends have leveled off and that Upwork’s enterprise pipeline is actually generating revenue. The company’s next earnings report lands May 6.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Legal & General share price slips as AI disruption worries keep UK insurers on edge
Previous Story

Legal & General share price slips as AI disruption worries keep UK insurers on edge

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Next Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Go toTop